A significant investment in the world’s first personalised heart failure prevention study was announced today to coincide with the annual European Heart Failure Awareness Day. The project is a collaboration between the pharmaceutical company Novartis and the Heartbeat Trust. The ground-breaking new study, entitled PARABLE*, aims to recruit 250 people over a two year period and will be the first project to be carried out by the new Dublin-based Innovation Centre for Personalised Medicine, which was launched in early 2015. The study, which will also be the first of its kind in the world, will shift the focus away from population-based intervention to a more targeted approach, which effectively focuses attention on those at higher risk of heart failure. This departure allows the million at risk of heart failure to be narrowed down to a cohort of 250,000 at the higher risk. Significantly, the project is focused on heart failure prevention versus treatment.